Fintel reports that on December 8, 2023, Citigroup initiated coverage of Prime Medicine (NYSE:PRME) with a Neutral recommendation.
Analyst Price Forecast Suggests 151.94% Upside
As of November 27, 2023, the average one-year price target for Prime Medicine is 21.57. The forecasts range from a low of 18.18 to a high of $27.30. The average price target represents an increase of 151.94% from its latest reported closing price of 8.56.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Prime Medicine is 2MM, an increase of ∞%. The projected annual non-GAAP EPS is -2.02.
What is the Fund Sentiment?
There are 106 funds or institutions reporting positions in Prime Medicine. This is an increase of 4 owner(s) or 3.92% in the last quarter. Average portfolio weight of all funds dedicated to PRME is 0.13%, a decrease of 12.64%. Total shares owned by institutions increased in the last three months by 28.91% to 11,913K shares. 
The put/call ratio of PRME is 0.40, indicating a bullish outlook.
What are Other Shareholders Doing?
ARKG - ARK Genomic Revolution ETF holds 2,223K shares representing 2.41% ownership of the company. In it's prior filing, the firm reported owning 1,796K shares, representing an increase of 19.20%. The firm increased its portfolio allocation in PRME by 1.21% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,364K shares representing 1.48% ownership of the company. No change in the last quarter.
PRNHX - T. Rowe Price New Horizons Fund holds 1,176K shares representing 1.27% ownership of the company. In it's prior filing, the firm reported owning 1,176K shares, representing a decrease of 0.03%. The firm decreased its portfolio allocation in PRME by 30.62% over the last quarter.
NAESX - Vanguard Small-Cap Index Fund Investor Shares holds 1,125K shares representing 1.22% ownership of the company. In it's prior filing, the firm reported owning 1,003K shares, representing an increase of 10.77%. The firm decreased its portfolio allocation in PRME by 23.48% over the last quarter.
XBI - SPDR(R) S&P(R) Biotech ETF holds 1,034K shares representing 1.12% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
